HER2-negative Breast Cancer Clinical Trials

73 recruitingLast updated: June 17, 2026

There are 73 actively recruiting her2-negative breast cancer clinical trials across 34 countries. Studies span Phase 2, Phase 1, Phase 3, Not Applicable, Phase 4. Top locations include Houston, Texas, United States, Boston, Massachusetts, United States, Nashville, Tennessee, United States. Updated daily from ClinicalTrials.gov.


HER2-negative Breast Cancer Trials at a Glance

73 actively recruiting trials for her2-negative breast cancer are listed on ClinicalTrialsFinder across 6 cities in 34 countries. The largest study group is Phase 2 with 38 trials, with the heaviest enrollment activity in Houston, Boston, and Nashville. Lead sponsors running her2-negative breast cancer studies include Fudan University, BeOne Medicines, and H. Lee Moffitt Cancer Center and Research Institute.

Browse her2-negative breast cancer trials by phase

Treatments under study

About HER2-negative Breast Cancer Clinical Trials

Looking for clinical trials for HER2-negative Breast Cancer? There are currently 61 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new HER2-negative Breast Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about HER2-negative Breast Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 73 trials

Recruiting
Phase 3

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+3 more
Relay Therapeutics, Inc.540 enrolled192 locationsNCT06982521
Recruiting
Phase 2

Capecitabine in ER+/HER2-negative Breast Cancer

Breast Cancer Stage IBreast Cancer Stage IIBreast Cancer Stage III+1 more
University Health Network, Toronto15 enrolled1 locationNCT07631052
Recruiting
Phase 1Phase 2

ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer

Breast CancerMetastatic Breast CancerBreast Cancer Female+2 more
Kristina A. Fanucci65 enrolled1 locationNCT07198724
Recruiting
Phase 2

Evaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With VEX Metronomic Chemotherapy and Concurrent or Delayed Radiotherapy in Patients With Advanced HER2-Negative Breast Cancer With Brain Metastasis

Brain Metastasis From Advanced HER2-negative Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences102 enrolled1 locationNCT06839560
Recruiting
Phase 1

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

Breast CancerOvarian CancerCervical Cancer+6 more
Regor Pharmaceuticals Inc.63 enrolled4 locationsNCT07524322
Recruiting
Phase 1

BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

Metastatic Breast CancerHER2-negative Breast CancerHormone Receptor-Positive Breast Cancer
BeOne Medicines120 enrolled15 locationsNCT06756932
Recruiting
Phase 2

Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

Metastatic Breast CancerHER2-negative Breast CancerMetaplastic Breast Carcinoma+1 more
The Methodist Hospital Research Institute36 enrolled3 locationsNCT05660083
Recruiting
Phase 2

A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast Cancer

Breast CancerHER2-Negative Breast CarcinomaHER2-negative Breast Cancer+2 more
Memorial Sloan Kettering Cancer Center176 enrolled7 locationsNCT07483307
Recruiting
Phase 1Phase 2

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Triple-Negative Breast CancerEndometrial CancerPrimary Peritoneal Carcinoma+12 more
Genmab884 enrolled66 locationsNCT05579366
Recruiting
Phase 2

Sacituzumab Govitecan In TNBC

Triple-Negative Breast CancerHER2-negative Breast CancerInvasive Breast Cancer+2 more
Massachusetts General Hospital260 enrolled5 locationsNCT04230109
Recruiting

DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients

Metastatic Breast CancerHER2-Negative Breast CarcinomaHER2-negative Breast Cancer+6 more
Mayo Clinic100 enrolled1 locationNCT06388122
Recruiting
Phase 1

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Metastatic Breast CancerHER2-negative Breast CancerAdvanced Solid Tumor+6 more
BeOne Medicines399 enrolled63 locationsNCT06120283
Recruiting
Phase 1

A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer

Breast CancerBreast Cancer MetastaticMetastatic Breast Cancer+5 more
Memorial Sloan Kettering Cancer Center28 enrolled7 locationsNCT06678269
Recruiting
Phase 2

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Breast CancerBreast NeoplasmHER2-negative Breast Cancer+7 more
Fudan University716 enrolled1 locationNCT05582499
Recruiting
Phase 1

Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy

Breast CancerHER2-negative Breast CancerHyperinsulinism
Yale University20 enrolled1 locationNCT05989347
Recruiting
Phase 2

Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy

HER2-negative Breast Cancer
Yale University140 enrolled1 locationNCT06953882
Recruiting
Phase 3

Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)

HER2-negative Breast CancerER Positive Breast CancerStage III Breast Cancer+1 more
European Organisation for Research and Treatment of Cancer - EORTC220 enrolled109 locationsNCT05512364
Recruiting
Phase 2

Neoadjuvant QL1706 in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer

HR-positive,HER2-negative Breast Cancer
RenJi Hospital55 enrolled1 locationNCT07396324
Recruiting
Phase 2

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Breast CancerBreast NeoplasmsHER2-negative Breast Cancer+8 more
QuantumLeap Healthcare Collaborative5,000 enrolled42 locationsNCT01042379
Recruiting
Phase 1Phase 2

Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer

Metastatic Breast CancerHR+/HER2-negative Breast Cancer
SynDevRx, Inc.52 enrolled10 locationsNCT05455619